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Abstract
Background: Weaning is the process during which mechanical ventilation is withdrawn and the work of breathing is transferred
from the ventilator back to the patient. Prolonged weaning is associated with development of ventilator-related complications
and longer stays in the Intensive Care Unit (ICU). Computerized or Automated Weaning is a novel weaning strategy that
continuously measures and adapts ventilator support (by frequently measuring and averaging three breathing parameters) and
automatically conducts Spontaneous Breathing Trials to ascertain whether patients can resume autonomous breathing.
Automated Weaning holds promise as a strategy to reduce the time spent on the ventilator, decrease ICU length of stay, and
improve clinically important outcomes.
Methods/Design: A pilot weaning randomized controlled trial (RCT) is underway in the ICUs of 8 Canadian hospitals. We will
randomize 90 critically ill adults requiring invasive ventilation for at least 24 hours and identified at an early stage of the weaning
process to either Automated Weaning (SmartCare™) or Protocolized Weaning. The results of a National Weaning Survey
informed the design of the Protocolized Weaning arm. Both weaning protocols are operationalized in Pressure Support mode,
include opportunities for Spontaneous Breathing Trials, and share a common sedation protocol, oxygen titration parameters,
and extubation and reintubation criteria. The primary outcome of the WEAN study is to evaluate compliance with the proposed
weaning and sedation protocols. A key secondary outcome of the pilot RCT is to evaluate clinician acceptance of the weaning
and sedation protocols. Prior to initiating the WEAN Study, we conducted a run-in phase, involving two patients per centre
(randomizing the first participant to either weaning strategy and assigning the second patient to the alternate strategy) to ensure
that participating centres could implement the weaning and sedation protocols and complete the detailed case report forms.
Discussion: Mechanical ventilation studies are difficult to implement; requiring protocols to be operationalized continuously
and entailing detailed daily data collection. As the first multicentre weaning RCT in Canada, the WEAN Study seeks to determine
the feasibility of conducting a large scale future weaning trial and to establish a collaborative network of ICU clinicians dedicated
to advancing the science of weaning.
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Background
Weaning is the process during which mechanical ventila-
tion is gradually or abruptly withdrawn. In addition, it is
the time during which work of breathing is transferred
from the ventilator back to the patient until fully autono-
mous breathing is resumed. Weaning accounts for
approximately 40% of the total time spent on mechanical
ventilation [1,2]. Invasive mechanical ventilation is asso-
ciated with the development of important complications
including ventilator associated pneumonia (VAP) [3],
sinusitis [4], upper airway pathology [3] and respiratory
muscle weakness [3]). VAP, in turn, is associated with
increased morbidity and a trend toward increased mortal-
ity [5]. Mechanical ventilation has recently been identified
as a key factor escalating intensive care unit (ICU) costs
[6]. For these reasons, minimizing exposure to prolonged
ventilation is an important goal of critical care medicine
[7].
Over the past decade, research has focused on strategies to
limit the duration of ventilation through early identifica-
tion of weaning candidates [8,10], the conduct of tests of
readiness to resume autonomous breathing [spontaneous
breathing trials (SBTs)] [11,13] and strategies to reduce
support in patients who fail a SBT [14,16]. Several modes
and techniques are used to facilitate weaning. The optimal
strategy to wean patients from invasive ventilation
remains unclear. Compared to traditional care, protocols
with their requirement for scheduled surveillance gener-
ally decrease the time to discontinuation and total dura-
tion of mechanical support [8-10]. Despite
demonstration of large-scale implementation, many bar-
riers exist to implementing weaning protocols in clinical
practice including the requirement for broad, educational
interventions and multidisciplinary compliance with
them [17,18].
Automated weaning systems use closed-loop control to
interpret clinical data in real time, perform basic and
advanced ventilator functions and enable interaction
between patients and the ventilator. Closed-loop systems
adapt ventilator output by comparing measured values to
targeted values of selected respiratory parameters and
either minimizing or equilibrating (negative feedback) or
amplifying (positive feedback) the differences between
these values [19]. SmartCare™ is a unique automated sys-
tem, specifically designed to guide weaning, that incorpo-
rates a closed-loop knowledge based system [20,21] into
an automated protocol that adapts the level of pressure
support provided to individual patient needs by opera-
tionalizing predetermined algorithms based upon respira-
tory rate (RR), tidal volume (VT) and end-tidal carbon
dioxide (ETCO2).
To initiate SmartCare™ end-users enter the patient's
weight, the presence or absence of chronic obstructive
pulmonary disease (COPD) or a central neurologic disor-
der, type of airway prosthesis (tracheostomy or oro/nasal
endotracheal tube) and the type of humidification
(heated humidification or heat and moisture exchanger)
in use. The first three parameters establish limits for RR, VT
and PETCO2 and the latter two items determine the thresh-
old to cycle into a SBT (range: 5 to 12 cm H2O). Smart-
Care™ categorizes patients into one of 8 diagnostic
categories based on average measurements of these
parameters made every 2 to 5 minutes. With SmartCare™,
patients may breathe with a RR ranging from 15 to 30
breaths/min (RR min) (alternatively, 34 breaths/min with
neurologic disease) (RR max), a VT above a minimum
threshold (VT Min = 250 ml if weight < 55 kg, or VT Min =
300 ml if weight ≥ 55 kg) and a PETCO2 below a maximum
threshold (max PETCO2 = 55 mmHg or max PETCO2 = 65
mmHg for COPD patients). SmartCare™ diagnosis a state
of normal ventilation when a patient's ventilatory param-
eters fall within these ranges. If patient parameters fall
outside of these ranges, an alternate diagnosis is made and
the system adjusts the level of pressure support provided
to attain these targets.
SmartCare™ automatically initiates a SBT when predeter-
mined thresholds of pressure support are reached [22,23]
in a state of normal ventilation with positive end-expira-
tory pressure (PEEP) is ≤ 5 cm H2O. This period is known
as an 'observation period' and varies from 30 minutes to
2 hours in duration. Upon successful completion of a SBT,
the ventilator issues a directive stating that the patient is
"ready for separation from ventilator". Prior to extuba-
tion, physicians must ensure that patients meet readiness
criteria to proceed with extubation. With SmartCare™, cli-
nicians titrate the fractional concentration of inspired oxy-
gen (FiO2) and PEEP. The automated algorithms may be
applied during the day or during the day and at night.
SmartCare™ has been evaluated in physiologic studies and
randomized controlled trials (RCTs). Similar to physician
assessments using conventional pressure support, Smart-
Care™ was demonstrated in two physiologic studies to be
capable of evaluating patient's ability to breathe sponta-
neously [22], decrease work of breathing, and reduce peri-
ods of respiratory distress during weaning [23]. A
prospective cohort study of 42 intubated critically-ill
patients, demonstrated that SmartCare™ could support
ventilation over prolonged time periods (up to 12 days)
[24]. Moreover, the system recognized patient's readiness
to undergo a SBT earlier than intensive care physicians
[24]. In a preliminary RCT involving 144 patients con-
ducted in 5 European centres, Lellouche and colleagues
showed that, compared to usual care directed by protocols
in most centres, SmartCare™ decreased the median dura-
tion of ventilation from 4 to 2 days (p = 0.02), total dura-
tion of ventilation (9 to 6.5 days, p = 0.03), median ICU
length of stay (15.5 to 12.0 days, p = 0.02) and nonsignif-Trials 2009, 10:81 http://www.trialsjournal.com/content/10/1/81
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icantly reduced the number of patients requiring pro-
longed ventilation (>21 days) (15.7 vs 6.7%, p = 0.11)
[25]. Conversely, in a single centre RCT in Australia, com-
paring SmartCare™ to usual care in 102 patients, Rose and
coworkers did not demonstrate reductions in weaning
time or complication rates [26]. Moreover, the generaliza-
bility of results from these regions to Canada where wean-
ing is a collaborative effort, involving registered
respiratory therapists (RRTs) and intensivists, is
unknown.
Objectives
The primary objective of the multicentre pilot study com-
paring SmartCare™ [hereafter referred to as "Automated
Weaning"] and "Protocolized Weaning" is to evaluate
compliance with the weaning and sedation protocols
among intubated patients requiring > 24 hrs of invasive
ventilation.
The secondary objectives of the multicentre pilot RCT are
to evaluate clinician acceptance of the alternative weaning
and sedation protocols using a Visual Analogue Scale
daily, and to demonstrate the ability to recruit the desired
patient population. In this manner, we will assess the fea-
sibility of conducting a future, definitive weaning RCT in
Canada.
Methods
Study Design
A pilot RCT is currently underway at 8 adult ICUs across
Canada in collaboration with the Canadian Critical Care
Trials Group. Ethics approval for the study was obtained
from the Research Ethics Board (REB) at St Michael's hos-
pital and the REBs of participating centres. Figure 1 pro-
vides an overview of the study.
Run-in Phase
Prior to initiating the pilot RCT, we conducted a "run-in
phase". The run-in phase included two patients at each
centre. While, the first patient was randomized to either
Automated Weaning or Protocolized Weaning, the second
patient was assigned to the alternative weaning strategy in
Study Flow Diagram Figure 1
Study Flow Diagram.
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a non-random manner. Upon completion of the two
patients, a clinical evaluation committee reviewed the
completed case report forms to assess (i) the ability of par-
ticipating centres to screen and enroll patients, (ii) com-
pliance with study procedures, and (iii) timeliness of data
collection and management. Approval from the clinical
evaluation committee enabled sites to proceed to enroll-
ing patients in the pilot RCT.
Patient Screening
A dedicated research coordinator at each site screens
patients for eligibility daily between 6:00 and 9:00 am at
each site. We use a staged process to (i) identify potential
study participants early in the weaning process and (ii)
obtain consent for a Pressure Support Trials (PST). If
patients fulfill the Criteria for Consent and have no exclu-
sion criteria, a member of the investigative team
approaches patients or their legal representatives for con-
sent to (i) undergo a PST (once the Criteria for a Pressure
Support Trial are attained) and a SBT (if criteria are met)
and (ii) randomization depending on the outcome of the
PST and SBT (see below).
Criteria for Consent
We developed criteria to enable early identification of
potential weaning candidates and to obtain consent early
in the weaning process. These criteria include:
1) invasive ventilation for > 24 hours,
2) at least partial reversal of the condition precipitat-
ing invasive ventilation,
3) stabilization of "other" organ system failures (i.e.
no worsening),
4) pulse oximetry oxygen saturation (SpO2) ≥ 90%
with fractional concentration inspired oxygen (FiO2) ≤
70%,
5) PEEP ≤ 12 cm H2O,
6) weight > 35 kg
7) the absence of exclusion criteria
We exclude patients (i) less than 16 years of age, (ii) with
a do not reintubate order documented on chart or antici-
pated withdrawal of life support, (iii) prolonged cardiac
arrest with poor neurological prognosis, (iv) a prior epi-
sode of invasive ventilation exceeding 24 hrs during the
same hospital stay, (v) tracheostomy, (vi) pregnancy, (vii)
known or suspected severe myopathy or neuropathy (i.e.,
Guillain-Barré syndrome) or quadriplegia, (viii) severe
heart failure (grade 3 or 4 left ventricular function or New
York Heart Association class 4 dyspnea).
Criteria for Pressure Support Trial
We consider consented patients, who meet the Criteria for
Consent, to undergo a PST at least once daily when they
meet the following criteria:
1) intubated patient on mechanical ventilation,
2) SpO2 ≥ 90% with FiO2 ≤ 50% and PEEP ≤ 10 cm
H2O,
3) no requirement for high dose vasopressors (i.e., no
epinephrine or norepinephrine > 15 µg/min (or 0.2
µg/kg/min) or equivalent dose vasopressin or phe-
nylephrine),
4) motor component of the Glasgow Coma Scale score
≥ 4 (withdraws to pain),
5) stable neurological status (no deterioration in the
last 24 hrs, intact respiratory drive, and intracranial
pressure < 20),
6) patient not expected to be extubated on the day of
study randomization,
7) no surgery or procedure requiring sedation planned
in the next 48 hrs.
We reassess criteria for a PST at least once daily after con-
sent is obtained.
Detailed Study Methods
Pressure Support Trials
PSTs are required to identify patients at the onset of the
recovery phase when patients are first able to tolerate
assisted ventilation. We adjust the level of pressure sup-
port provided to obtain a RR ≤ 35 breaths/min during
PSTs. The initial level of pressure support is set at 15 cm
H2O for patients not already on this mode and at the cur-
rent level of pressure support in patients already on pres-
sure support. PSTs are at least 60 consecutive minutes and
not longer than 120 minutes in duration. The maximal
pressure support (above PEEP) is 22 cm H2O and the min-
imum is 10 cm H2O. A PST can be stopped at any time for
sustained hemodynamic or respiratory distress (heart rate
≤ 50 or ≥ 140 beats per minute or new significant dys-
rhythmias, systolic blood pressure ≤ 80 mm Hg or ≥ 180
mm Hg or RR > 40 breaths/min).
A PST is considered successful if after 60 consecutive min-
utes without a change in the level of pressure support, the
patient remains clinically stable with a RR less than or
equal to 35 and greater than 10 breaths/min with no
decrease in pulse oximetry saturations (SpO2 remains ≥
90% on an FiO2 ≤ 50% with PEEP ≤ 8 cm H2O). Patients
who fail a PST are returned to their previous ventilator set-Trials 2009, 10:81 http://www.trialsjournal.com/content/10/1/81
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tings or settings that restore respiratory comfort. We reas-
sess these patients at least daily for criteria to undergo a
PST. Patients who successfully complete a PST are assessed
for a SBT. Patients who do not meet SBT criteria (i.e., are
too early to undergo a SBT) are randomized upon success-
ful completion of a PST.
Spontaneous Breathing Trials
Since patients who successfully complete a PST include
those who do and do not require further weaning, we con-
duct an SBT with the goal of identifying patients who can
tolerate pressure support but fail an SBT. These individu-
als are regarded as requiring further weaning. We consider
patients with (i) partial or complete reversal of the cause
of respiratory failure with SpO2 ≥ 90% on an FiO2 ≤ 0.4
(or at baseline level in chronically hypoxemic patients)
and PEEP ≤ 5 cm H2O, (ii) hemodynamic stability [off
vasopressors or on low levels of vasopressors (i.e., lev-
ophed ≤ 7 µg/min or ≤ 0.1 µg/kg/min) or equivalent], (iii)
absence of uncontrolled sepsis, and (iv) stable haemo-
globin > 70 g/L to undergo a SBT. We conduct SBTs of 30
to 120 minutes duration using either a T-piece with oxy-
gen or continuous positive airway pressure (CPAP) ≤ 5 cm
H2O or PSV of 5 - 7 cm H2O (using a heated humidifier or
alternatively, 10-12 cm H2O with a heat and moisture
exchanger) [27,30] with or without 5 cm H2O PEEP.
Patients who successfully complete a SBT are considered
for extubation (i.e., do not require further weaning). Con-
versely, patients who fail a SBT are randomized. We con-
sider the presence of any one of the following: (i) RR > 35
breaths/min, (ii) clinical signs of respiratory distress (i.e.,
abdominal paradox), (iii) SpO2 < 90% (or below baseline
in chronically hypoxemic patients) with FiO2 > 50%, (iv)
systolic blood pressure ≤ 80 mmHg or ≥ 180 mmHg, (v)
heart rate ≤ 50 or ≥ 140 beats/min or new significant dys-
rhythmias, (vi) severe agitation or diaphoresis, or (vii)
Increased somnolence with elevated arterial pressure of
carbon dioxide (PaCO2) and pH < 7.30 to signify SBT fail-
ure. In summary, we randomize consented patients
requiring pressure support of at least 10 cm H2O who (i)
successfully complete a PST, but DO NOT meet criteria to
undergo a SBT (i.e., are too early to undergo a SBT) or (ii)
who successfully complete a PST and fail a SBT.
Study Randomization
Patients undergo stratified randomization within centres
based on the presence (or absence) of (i) a diagnosis of
known or suspected COPD [31,32] or (ii) a central neuro-
logic disorder, provided that a study ventilator is availa-
ble. In the event that both diagnoses are present, we
prioritize central neurologic disorders during stratifica-
tion.
Weaning Procedures
Randomized patients are initiated on either the Auto-
mated Weaning or Protocolized Weaning algorithms until
extubation criteria are achieved. All patients will be fol-
lowed until successful extubation, ICU death, ICU dis-
charge or until 90 days after randomization (deemed
ventilator dependent).
a) Ventilators
We use the Evita XL ventilator (which includes Smart-
Care™) or, alternatively, the Evita 2 dura or Evita 4 venti-
lators with a SmartCare™ ventilator upgrade in patients
randomized to the Automated Weaning strategy. We
equipped participating centres with a minimum of two of
these ventilators. Comparable third generation ventilators
(Evita 2 dura, Evita 4, Evita XL, Servo i, Servo 300, Puritan
Bennett 840, Puritan Bennett 760, Avea or Galileo) are
used in the Protocolized Weaning arm. We preferentially
use Evita ventilators in the Protocolized Weaning arm if
additional ventilators, when available.
b) Humidification systems and ventilator circuits
We clustered use of different forms of humidification to
warm inspired air in the WEAN study to gain experience
in the interaction of different forms of humidfication with
the automated algorithm. We use heated humidifiers
(MR850, Fisher & Paykel; Auckland, New Zealand) in
both study arms in 5 centres and heat and moisture
exchangers at 3 centres, to gain experience with the inter-
action between humidification and the Automated Wean-
ing system. We record changes from one humidification
strategy to another in the event difficulties (secretion vol-
ume, alarms etc) on the data collection forms. We use
either RT 110 or RT 240 (Evaqua™) circuits in the WEAN
study. Reusable circuits are not permitted.
c) Ventilator strategies and alarms
Regardless of the strategy to which the patient is rand-
omized, the initial pressure support setting is similar to
that used during the PST. In both groups, pressure support
may increase or decrease during weaning according to
patient needs or events (i.e., mucous plugging, anxiety).
We present the details including initiation, titration and
discontinuation) of the Automated Weaning and Proto-
colized Weaning strategies (in Additional file 1, Appendi-
ces 1 and 2). We set the maximum inspiratory pressure to
35 cm H2O in the Automated Weaning arm.
d) Criteria to suspend weaning protocols/return to an alternate mode 
of ventilation
In both groups, patients are permitted to return to or
remain on alternate modes of ventilation for: (i) surgery
or invasive procedures requiring sedation, (ii) respiratory
distress defined by a) sustained hypoxemia (SpO2 < 90%)
with FiO2 > 60% and PEEP > 10 cm H2O or hypercapnia
with pH < 7.30 or clinical respiratory distress, b) repeated
episodes (≥ 3 episodes within 1 hour wherein an inspira-
tory pressure (pressure support + PEEP) of 35 cmH2O is
attained (despite suctioning, bronchodilation etc.), (iii)Trials 2009, 10:81 http://www.trialsjournal.com/content/10/1/81
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hemodynamic instability despite fluid boluses and the
requirement for high dose vasopressors: norepinephrine >
15µg/min (0.2µg/kg/min) or equivalent, (iv) suspected
myocardial ischemia based on electrocardiogram and/or
elevated Troponin i, (v) neurologic deterioration with
need to control PaCO2 (both groups) or alarm indicating
"Central hypoventilation" (Automated Weaning), (vi) a
requirement for increased sedation resulting in RR < 10
breaths/min. Patients meeting a criterion, are reassessed at
least daily with PSTs to identify the earliest time when
weaning can be resumed according to the assigned treat-
ment. However, the pre-randomization requirement to
undergo a SBT (if criteria are present) is not required at
this time point.
e) Reintubation and implications for ventilator management
In the Automated Weaning arm, a ventilator capable of
delivering SmartCare™ is kept in the patient's room fol-
lowing extubation until the patient is deemed successfully
extubated [off non-invasive (NIV) or invasive positive
pressure ventilation for 48 consecutive hours]. Patients
remain on the assigned strategy until ICU discharge, ICU
death, successful extubation or until day 90 following ran-
domization. Patients requiring reintubation in the Auto-
mated Weaning arm within 48 hours of extubation will be
weaned using SmartCare™ as soon as possible (i.e., upon
successful completion of a PST). All patients that require
reintubation after successful extubation will be ventilated
according to usual practice.
f) Sedation titration
We developed a sedation guide to guide sedation admin-
istration and limit performance bias during weaning. Crit-
ical care nurses titrate sedation to achieve either a
Sedation Agitation Scale (SAS) [33] score of 3 to 4 (see
Additional file 1, Appendix 3) or a Richmond Agitation
Scale Score (RASS) [34] of -3 to 0 [35]. Sedation titration
is not mandatory in patients meeting criteria to return to
or remain on an alternate mode of ventilation.
g) Other considerations
We developed a PEEP/FiO2 chart to guide their titration
during weaning (see Additional file 1, Appendix 4). Use of
the PEEP/FiO2 chart is not mandatory for patients meeting
criteria to return to or remain on an alternate mode of
ventilation.
Additional important considerations in developing the
WEAN Study protocol include (i) the initiation and use of
NIV following extubation [36,37], (ii) reintubation and
reinitiation of weaning [38] and (iii) performance of a tra-
cheostomy (Additional file 1, Appendix 5). For patients
randomized to Automated Weaning, the data entered to
initiate the system must be re-entered following a trache-
ostomy or change in humidification device prior to recon-
nection.
Study Outcomes
The primary outcome of the WEAN pilot study is compli-
ance with the weaning and sedation protocols. Secondary
outcomes include (i) daytime clinician (nurse; RRT and
physician) acceptance of the sedation and weaning proto-
cols, respectively, (ii) time to successful extubation
defined as the time from randomization to unsupported
(no requirement for NIV or invasive ventilation), sponta-
neous breathing for ≥ 48 hours after extubation (or dis-
connection with a tracheostomy), (iii) time to completion
of a successful SBT, (iv) total duration of mechanical ven-
tilation (time from intubation to termination of ventila-
tion), (vi) ICU and hospital length of stay, (vii) ICU and
hospital mortality, and the proportion of patients (viii)
developing nosocomial pneumonia [39], (ix) with wean-
ing (self-extubation, tracheostomy, reintubation and pro-
longed mechanical ventilation >21 days) or ICU
(myocardial infarction and pneumothoraces) complica-
tions, and (x) requiring NIV. Any NIV use is considered
clinically relevant.
Data Collection
We collect data at ICU admission, study inclusion and
daily thereafter. Whereas protocol violations (non com-
pliance) in the Automated Weaning arm include return
to/remain on an alternate mode of mechanical ventilation
in the absence of meeting criteria and any unauthorized
interruptions (cessations, manual increases/decreases) in
the automated protocol, violations in the Protocolized
Weaning group include unauthorized use of modes other
than pressure support (i.e., assist control) without criteria
to return to or remain on an alternate mode of mechanical
ventilation. We tabulate a daily score reflecting the
number of SBTs conducted divided by the number of
required SBT assessments in which all criteria were met in
the Protocolized Weaning group. Sedation protocol com-
pliance is assessed by the percentage of daily SAS scores <
2 or > 5 (or alternatively, RASS scores < - 4 or > +1) in both
arms. We also evaluate compliance with the PEEP/FiO2
chart in both groups. RRT and physician acceptance of the
weaning protocols and critical care nurse acceptance of
the sedation protocol is assessed daily using Likert [40]
scales [ranging from 0 highly unacceptable (extremely dif-
ficult to use) to 10 highly acceptable (extremely easy to
use)].
Statistical Analyses
Descriptive statistics including means, standard devia-
tions, medians, interquartile ranges and frequency distri-
butions will be used to summarize the data. For univariate
analyses, we will use the Chi-square test (alternatively,
Fisher's exact test when the expected value is ≤ 5) and Stu-
dent's t-test (alternatively, the Mann-Whitney U-test, if
normality assumptions are not satisfied) for binary and
continuous outcomes, respectively. We will evaluate the
percentage of (i) hours off-protocol and (ii) daily SASTrials 2009, 10:81 http://www.trialsjournal.com/content/10/1/81
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scores < 2 or > 5 (or RASS equivalent) by treatment group.
Compliance will be considered acceptable if ≥ 75% [that
is; protocol violations (off protocol hours without meet-
ing criteria to return to/remain on an alternate mode of
mechanical ventilation) or SAS scores < 2 or > 5 (equiva-
lent RASS -4 < or > +1) occur < 25% of the time]. SBT com-
pliance will be considered acceptable if ≥ 75% of SBT
opportunities are realized. We will compare average Likert
scale scores based on clinician group and the weaning
strategy utilized using Analysis of Variance (ANOVA). We
will compare time to successful extubation and death
between groups using time-to-event analysis with censor-
ing of deaths and application of the log-rank test. We will
consider p-values ≤ 0.05 to be statistically significant.
Sample Size
Estimates are not available to allow precise sample size
estimation of the primary outcome for the multicentre
pilot RCT. To ensure that the study protocols are easy to
follow before engaging in a definitive weaning RCT, we
estimate that a total of 90 patients (ideally approximately
11-12 patients per site) are required to assess protocol
compliance. To ensure that all centres gain some experi-
ence with both protocols, we set a maximum site enrol-
ment of 35 patients.
Discussion
Life support technology interventions account for 5-10%
of acute care bed occupancy and 34% of hospital budgets
[41]. Current demands are expected to escalate in the
future as the middle sector of our population ages [42].
Since up to 40% of the time on mechanical ventilation is
related to weaning, Automated Weaning holds promise as
a strategy to reduce ICU length of stay and the total time
spent on mechanical ventilation by reducing weaning
time, and weaning and ICU-related complications. More
importantly, Automated Weaning may reduce the burden
of illness related to protracted invasive ventilation and
improve patient-important outcomes [43]. A key benefit
of SmartCare™ is that weaning is unencumbered by lim-
ited clinician availability in the busy ICU setting. Prior to
conducting a full scale RCT comparing the effect of the
alternative weaning strategies on important clinical out-
comes, we designed a feasibility RCT to assess clinician
compliance with and acceptance of the detailed weaning
and sedation protocols [44].
In the absence of evidence regarding the current 'standard
of care in weaning' in Canada, we developed, tested and
administered a questionnaire to RRT and physician lead-
ers using rigorous survey methodology [45] to identify key
aspects of weaning (use of protocols, daily screening, con-
duct of SBTs, preferred methods of support) at Canadian
teaching hospitals. In this manner, we identified that daily
screening and pressure support were common features of
weaning and that most centres conduct SBTs using one of
three strategies [46]. The results of the National Weaning
Survey informed the design of the paper-based weaning
protocol (control arm) in the WEAN Study.
Prior to initiating the multicentre WEAN Study, we con-
ducted a run-in phase study involving two patients per
centre. We randomized the first participant at each centre
to either Automated or Protocolized Weaning and
assigned the second patient to the alternate weaning strat-
egy. We conducted the run in phase to ensure that partic-
ipating centres could implement the detailed weaning and
sedation protocols and complete the case report forms.
Mechanical ventilation studies require detailed daily data
collection and for protocols to be operationalized contin-
uously. Following review of run in phase study proce-
dures, a clinical evaluation committee approved sites to
proceed with enrollment in the WEAN pilot RCT.
Conclusion
The WEAN pilot study was designed to evaluate clinician
compliance with and acceptance of the proposed weaning
and sedation protocols. In addition, we will ascertain
whether centres can recruit the desired patient popula-
tion. Strengths of the WEAN Study include the use of cen-
tral randomization, allocation concealment, stratification
(to ensure equal distribution of conditions that may pro-
long ventilation) and the use of protocols in both arms to
limit treatment and performance bias. To this end, both
treatment arms use pressure support and include opportu-
nities to undergo SBTs. Moreover, they share a common
PEEP/FiO2 chart, sedation protocol, extubation and rein-
tubation criteria, and criteria for NIV use for post-extuba-
tion respiratory failure. The major threat to the validity of
the pilot RCT is that it is, out of necessity, unblinded. To
this end, we developed detailed weaning and sedation
protocols to limit potential sources of bias and standard-
ize weaning and sedation administration in both study
arms and across participating centres. While we can not
blind clinicians, patients and data collectors, we will blind
the data analyst to treatment group assignment until the
planned statistical analyses are completed. As the first
multicentre weaning RCT in Canada, the WEAN Study
seeks not only to determine the feasibility of conducting a
large scale future weaning trial, but to establish a collabo-
rative network of ICU clinicians dedicated to advancing
the science of weaning.
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